V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215331 | 20081466 | 1.66 | 81.2 | null | 2020-09-21 | 2020-09-26 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100810025 |
| 20215333 | 20081467 | 1.61 | 75.9 | Palliative (P) | 2019-03-07 | 2019-03-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101635695 |
| 20215334 | 20081468 | 1.68 | 62 | Curative (C) | 2019-09-19 | 2019-09-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 100547247 |
| 20215335 | 20081469 | 1.74 | 62.5 | Palliative (P) | 2018-07-06 | 2018-07-06 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101038282 |
| 20215337 | 20081470 | 1.66 | 69.8 | Neo-adjuvant (N) | 2020-02-20 | 2020-02-26 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 100853397 |
| 20215338 | 20081471 | 1.7 | 66.4 | Curative (C) | 2016-02-25 | 2016-03-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100170146 |
| 20215340 | 20081472 | 1.82 | 0 | Curative (C) | 2019-09-24 | 2019-09-29 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101486981 |
| 20215341 | 20081473 | 1.83 | 72.6 | Palliative (P) | 2017-09-08 | 2017-09-09 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101052276 |
| 20215342 | 20081474 | 1.56 | 79.8 | null | 2018-11-14 | 2018-11-20 | Imatinib 400mg | 02 | null | IMATINIB | 101462380 |
| 20215343 | 20081475 | 1.62 | 103 | Curative (C) | 2016-06-22 | 2016-08-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101695982 |
| 20215344 | 20081476 | 1.8 | 126 | Curative (C) | 2019-07-06 | 2019-08-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101742935 |
| 20215346 | 20081477 | 1.67 | 80.5 | Palliative (P) | 2019-03-25 | 2019-03-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101019227 |
| 20215347 | 20081478 | 1.71 | 89.2 | Palliative (P) | 2019-11-18 | 2019-11-22 | HCX | 02 | N | LANREOTIDE | 101831025 |
| 20215348 | 20081479 | 1.69 | 96.1 | Palliative (P) | 2019-04-29 | 2019-05-06 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101836126 |
| 20215349 | 20081480 | 1.62 | 51 | Palliative (P) | 2018-07-21 | 2018-08-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101565501 |
| 20215350 | 20081481 | 0 | 66.8 | Palliative (P) | 2017-12-11 | 2018-01-03 | Imatinib 400mg | 02 | N | IMATINIB | 101285932 |
| 20215351 | 20081482 | 1.58 | 64 | Palliative (P) | 2018-05-04 | 2018-05-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101417693 |
| 20215352 | 20081483 | 1.68 | 80 | Palliative (P) | 2019-06-16 | 2019-07-05 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101263046 |
| 20215354 | 20081484 | 1.66 | 93.8 | 03 | 2018-11-20 | 2018-11-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100556544 |
| 20215355 | 20081485 | 1.75 | 74.9 | null | null | 2017-11-26 | LANREOTIDE | 02 | null | LANREOTIDE | 101560795 |
| 20215356 | 20081486 | 1.9 | 64.8 | Palliative (P) | 2017-10-11 | 2017-10-11 | Trial Unspecified | Y | N | TRIAL | 101067631 |
| 20215357 | 20081487 | 1.68 | 61.8 | Neo-adjuvant (N) | 2016-03-21 | 2016-03-24 | Imatinib 400mg | null | null | IMATINIB | 100350582 |
| 20215358 | 20081488 | 1.6 | 84.4 | null | 2019-06-03 | 2019-06-18 | HCX | 02 | N | LANREOTIDE | 101339318 |
| 20215359 | 20081489 | null | null | Palliative (P) | 2018-12-24 | 2019-01-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100609920 |
| 20215361 | 20081490 | 1.7 | 76.5 | null | 2019-04-13 | 2019-05-04 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100729202 |
| 20215362 | 20081491 | 1.84 | 45 | Palliative (P) | 2019-08-21 | 2019-08-25 | Imatinib 400mg | 02 | N | IMATINIB | 101841056 |
| 20215363 | 20081492 | 1.67 | 82.6 | Palliative (P) | 2019-12-13 | 2020-01-13 | Trial Unspecified | 01 | N | TRIAL | 100193452 |
| 20215364 | 20081493 | 1.69 | 75 | null | 2016-11-28 | 2016-12-02 | IMATINIB | 02 | null | IMATINIB | 101452528 |
| 20215365 | 20081494 | 1.68 | 65.3 | Palliative (P) | 2016-09-27 | 2016-09-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101375192 |
| 20215366 | 20081495 | 1.66 | 89 | null | 2018-06-05 | 2018-06-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101777888 |
| 20215367 | 20081496 | 1.54 | 90.5 | Palliative (P) | 2019-06-01 | 2019-06-14 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101337808 |
| 20215371 | 20081497 | null | 80.7 | null | 2016-04-02 | 2016-04-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101781786 |
| 20215372 | 20081498 | 1.8 | 69.6 | Adjuvant (A) | 2019-02-16 | 2019-03-12 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 101201343 |
| 20215373 | 20081499 | 1.7 | 63.1 | Palliative (P) | 2019-01-05 | 2019-01-08 | LANREOTIDE | 02 | N | LANREOTIDE | 100521098 |
| 20215374 | 20081500 | 1.76 | 83.2 | Adjuvant (A) | 2018-03-23 | 2018-04-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100984879 |
| 20215375 | 20081501 | 1.7 | 68 | Curative (C) | 2018-05-21 | 2018-05-25 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101043799 |
| 20215376 | 20081502 | 1.7 | 70.5 | null | 2016-02-02 | 2016-03-06 | HCX | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100504378 |
| 20215378 | 20081503 | 1.6 | 78.9 | Palliative (P) | null | 2016-11-05 | Trial Unspecified | 01 | N | TRIAL | 101336553 |
| 20215379 | 20081504 | 1.72 | 97.3 | null | 2019-01-17 | 2019-01-22 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100816064 |
| 20215380 | 20081505 | 1.53 | null | Disease modification (D) | 2018-01-01 | 2018-01-09 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101051056 |
| 20215382 | 20081506 | 1.56 | 63.2 | Curative (C) | 2017-01-14 | 2017-01-22 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101317150 |
| 20215383 | 20081507 | 1.59 | 73.3 | Palliative (P) | 2018-08-23 | 2018-10-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100469529 |
| 20215384 | 20081508 | null | 64.5 | Curative (C) | 2019-08-25 | 2019-08-26 | Imatinib 400mg | 02 | N | IMATINIB | 100170904 |
| 20215385 | 20081509 | 1.78 | 63.2 | Palliative (P) | 2019-05-19 | 2019-05-31 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100386693 |
| 20215386 | 20081510 | 1.86 | 68.4 | Curative (C) | 2016-09-02 | 2016-09-02 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101232713 |
| 20215388 | 20081511 | 1.8 | 76.9 | Disease modification (D) | 2017-04-15 | 2017-05-04 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 101772614 |
| 20215389 | 20081512 | 1.84 | 90 | null | 2018-11-22 | 2018-11-24 | LANREOTIDE | 02 | null | LANREOTIDE | 101009639 |
| 20215390 | 20081513 | 1.74 | 65.3 | Curative (C) | 2018-11-04 | 2018-11-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100711634 |
| 20215391 | 20081514 | 1.63 | 59 | Palliative (P) | 2016-04-11 | 2016-04-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101152814 |
| 20215392 | 20081515 | 1.8 | 0 | Palliative (P) | 2017-04-03 | 2017-04-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100944746 |